RT Book, Section A1 Wellstein, Anton A1 Giaccone, Giuseppe A1 Atkins, Michael B. A1 Sausville, Edward A. A2 Brunton, Laurence L. A2 Hilal-Dandan, Randa A2 Knollmann, Björn C. SR Print(0) ID 1162546947 T1 Cytotoxic Drugs T2 Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 13e YR 2017 FD 2017 PB McGraw-Hill Education PP New York, NY SN 9781259584732 LK hemonc.mhmedical.com/content.aspx?aid=1162546947 RD 2024/03/28 AB A Note on Treatment RegimensCancer treatment regimens change to reflect continuous advances in basic and clinical science: new drugs, both small molecules and biologicals; improved methods of targeting and timing of drug delivery; agents with altered pharmacokinetic properties and selectivities; the use of rational multidrug combinations; and greater knowledge of the basic cell biology of tumorigenesis, metastasis, and immune function, amongst other advances. As a consequence, this chapter presents relatively few detailed treatment regimens; rather, we refer the reader to the web-based resources of the U.S. FDA and the NCCN. Table 67–1 provides two examples of therapeutic regimens that illustrate the complexity of current cancer drug therapy.